^
    1d
    SPRINT 2: The Selective Personalized Radio-Immunotherapy for Locally Advanced Non-Small Cell Lung Cancer Trial 2 (clinicaltrials.gov)
    P2, N=52, Not yet recruiting, Montefiore Medical Center | Trial completion date: Oct 2028 --> Feb 2029 | Initiation date: May 2026 --> Sep 2026 | Trial primary completion date: Dec 2027 --> Apr 2028
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Imfinzi (durvalumab) • oleclumab (MEDI9447) • monalizumab (IPH2201)
    24d
    Glycerol-mediated nose-to-brain codelivery of anti-IL-17 and anti-CD73 antibodies enhances immunotherapy for melanoma brain metastases. (PubMed, Sci Adv)
    Ultimately, this combination promoted CD8+ T cell activation and residency, pro-inflammatory macrophage polarization, and reduced Treg cell infiltration, thereby eliciting a strong antitumor effect. Our results establish an efficient nose-to-brain delivery platform for macromolecules and propose a therapeutic strategy for tumors using anti-IL-17 to overcome TME-imposed limitations in CD73-targeted immunotherapy.
    Journal
    |
    CD8 (cluster of differentiation 8) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • IL17A (Interleukin 17A)
    26d
    A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA) (clinicaltrials.gov)
    P2, N=30, Active, not recruiting, AstraZeneca | Trial completion date: Jun 2027 --> Mar 2027
    Trial completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
    |
    EGFR wild-type • ALK wild-type
    |
    Imfinzi (durvalumab) • oleclumab (MEDI9447)
    28d
    A Phase I/II Study of TJ004309 for Advanced Solid Tumor (clinicaltrials.gov)
    P1/2, N=225, Completed, TJ Biopharma Co., Ltd. | Active, not recruiting --> Completed | N=376 --> 225
    Trial completion • Enrollment change • IO biomarker
    |
    Loqtorzi (toripalimab-tpzi) • uliledlimab (TJD5)
    1m
    Metabolism, Excretion, and Mass Balance Study of Quemliclustat in Healthy Adult Participants (ARC-24) (clinicaltrials.gov)
    P1, N=8, Completed, Arcus Biosciences, Inc. | Active, not recruiting --> Completed
    Trial completion
    |
    quemliclustat (AB680)
    2ms
    Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases (clinicaltrials.gov)
    P2, N=24, Recruiting, Weill Medical College of Cornell University | Trial completion date: Mar 2027 --> Dec 2027 | Trial primary completion date: Sep 2026 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    MSI (Microsatellite instability)
    |
    balstilimab (AGEN2034) • botensilimab (AGEN1181) • dalutrafusp alfa (AGEN1423)
    3ms
    CHANCES: A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=27, Recruiting, Institut Paoli-Calmettes | Trial completion date: Feb 2026 --> Mar 2027 | Trial primary completion date: Mar 2025 --> Mar 2027
    Trial completion date • Trial primary completion date • First-in-human
    |
    PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA (Breast cancer early onset)
    |
    PD-L1 expression • HER-2 positive • HER-2 amplification • HER-2 expression • BRCA mutation • PD-L1 expression + HER-2 overexpression
    |
    Herceptin (trastuzumab) • paclitaxel • IPH5301
    3ms
    Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=87, Recruiting, Akeso | Trial completion date: Dec 2024 --> Jun 2027 | Trial primary completion date: Jun 2024 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    Idafang (ivonescimab) • drebuxelimab (AK119)
    3ms
    Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients (clinicaltrials.gov)
    P1/2, N=59, Terminated, Akeso | N=114 --> 59 | Recruiting --> Terminated; Terminated due to sponsor strategic development reprioritization.
    Enrollment change • Trial termination
    |
    EGFR mutation
    |
    carboplatin • pemetrexed • Idafang (ivonescimab) • drebuxelimab (AK119)
    3ms
    Metabolism, Excretion, and Mass Balance Study of Quemliclustat in Healthy Adult Participants (ARC-24) (clinicaltrials.gov)
    P1, N=8, Active, not recruiting, Arcus Biosciences, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    quemliclustat (AB680)
    3ms
    A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer (clinicaltrials.gov)
    P1/2, N=170, Active, not recruiting, Akeso | Recruiting --> Active, not recruiting
    Enrollment closed • pMMR
    |
    MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2)
    |
    5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • Idafang (ivonescimab) • drebuxelimab (AK119)
    4ms
    Metabolism, Excretion, and Mass Balance Study of Quemliclustat in Healthy Adult Participants (ARC-24) (clinicaltrials.gov)
    P1, N=8, Recruiting, Arcus Biosciences, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    quemliclustat (AB680)